"Technology challenges are not roadblocks — they are opportunities to reimagine how we deliver safer and more sustainable solutions" Post this "Technology challenges are not roadblocks — they are opportunities to reimagine how we deliver safer and more sustainable solutions," said O'Malley. "I'm honored to join this conversation at MEDevice Boston and look forward to sharing how collaboration and innovation can help us break barriers in MedTech." Joining O'Malley on the panel are distinguished leaders shap ...

Key Takeaways Insulet shares surged 37.4%, far outpacing the industry and the benchmark's gains over the past year.Insulet's Omnipod 5 momentum, iPhone app launch and CGM integrations are driving strong adoption.Expansion in Europe, new U.S. digital tools and label growth strengthen Insulet's market position.Insulet (PODD) has seen impressive momentum in the past year, with its shares soaring 37.4%. It has significantly outperformed the industry’s 0.5% fall and the S&P 500 composite’s 17.5% gain.Presently c ...

Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued at $23.6 billion by market cap, the company develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Companies worth $10 billion or more are generally described as “large-cap stocks,” and PODD perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the medical device ...

This story was originally published on CFO.com. To receive daily news and insights, subscribe to our free daily CFO.com newsletter. Selim Freiha | Opendoor Opendoor’s CFO, Selim Freiha, will leave the company effective today, according to a securities filing. Freiha joined the online real estate platform in November 2024 from Google’s parent company, Alphabet, where he served as vice president of capital allocation and planning. Freiha will be succeeded by Christy Schwartz as interim chief financial office ...

ClearBridge Investments, an investment management company, released its “ClearBridge Select Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equities strongly rebounded in the second quarter. The S&P 500 Index returned 10.9%, and the benchmark Russell 3000 Index advanced 11.0%, as risk-on sentiment took hold following the pause in tariff implementation. The strategy outperformed the benchmark in the quarter, driven by the strength in portfolio construction acr ...

核心观点 - 全球糖尿病技术巨头Insulet正在通过系统性的高管团队重组 加速构建具有跨国医疗科技与消费健康背景的新管理架构 以匹配其全球化扩张和商业模式升级的战略需求 这一调整发生在公司业绩表现强劲、新用户增长超预期的背景下 属于高位主动升级而非危机应对 [4][6][8][10] 管理层重组 - 2025年9月16日宣布由强生老将Flavia Pease接任执行副总裁兼首席财务官 接替自2022年起任职的Ana Maria Chadwick 过渡安排在9月30日正式生效 原CFO转任公司高级顾问确保平稳交接 [2] - 新CFO Flavia Pease在强生工作超过二十年 长期负责财务管理和战略规划 并于2024年初加入Insulet董事会 对公司业务已相当熟悉 [3] - 此次CFO变更是一系列高管调整的最新动作：8月Eric Benjamin从首席产品与消费者体验官升任首席运营官 新设首席增长官由前强生高管Manoj Raghunandanan担纲 另任命Amit Guliani为下一任首席技术官 [3] 战略意图 - 管理层呈现"J&J化"趋势：从CEO到CFO再到CGO 多位核心高管均拥有长期强生任职经历 这是公司基于行业环境的战略选择 [4] - 通过"老牌跨国背景+新兴糖尿病科技"结合 塑造兼具产品敏感度、资本视野与全球执行力的管理团队 [6] - 强生背景高管带来三方面价值：强化全球化运营与合规经验以拓展欧洲、亚洲等新兴市场 提升"消费品+医药+器械"的跨界融合能力以推动系统解决方案 增强资本运作与并购整合能力以加速技术布局 [8] 业绩表现 - 在公布CFO交接同时释放关键信息：预计第三季度收入将超过此前指引 美国本土及国际市场的新用户增长均超出预期 [8] - 管理层调整发生在业绩表现强劲、用户基础扩张阶段 属于战略主动而非经营危机驱动的被动调整 [8][10] - 通过"战略调整+业绩向好"的组合信号强化资本市场信心 原CFO转任顾问保障团队稳定 新CFO强化跨国财务与战略背景以平衡扩张与风险 [9] 行业趋势 - 跨国制药与医疗器械公司高管向细分赛道企业流动成为趋势 这是创新企业以成熟人才体系强化竞争力的捷径 [11] - CFO更迭预示资本运作新动作 跨国财务经验有助于提升二级市场沟通效率和并购整合能力 [11] - 糖尿病管理正处于技术演进与用户教育并行的关键期 需同时解决技术升级与患者接受度的双重挑战 消费健康与数字医疗背景的管理者能更好应对这种需求 [11]

公司人事任命 - 医疗设备公司Insulet任命行业资深人士Flavia Pease担任新任首席财务官 [1] 财务表现 - 公司预计第三季度总营收将超过先前发布的指引 [1]

公司人事变动 - Insulet任命资深财务高管Flavia Pease为新任首席财务官 自2025年9月30日起生效 [1] - 原首席财务官Ana Maria Chadwick将留任高级顾问以协助过渡 [1] - Pease最近任职公司高管职务 [1]

公司财务表现 - 2024年公司营收超过20亿美元 [4] - 全球客户数量超过50万 其中超过35万使用旗舰产品Omnipod 5 [4] 市场地位与产品优势 - 公司是全球糖尿病技术领域领导者之一 [4] - 在全球胰岛素泵市场（规模达47亿美元）处于领先地位 [1] - 业务覆盖全球25个市场 [4] - Omnipod 5是美国首个获批用于1型和2型糖尿病的自动胰岛素输送系统 [4] 管理层信息 - 首席财务官为Ana Maria Chadwick [1] - 首席运营官为Eric Benjamin 近期获得晋升 [1][2]

Insulet (NasdaqGS:PODD) 2025 Conference September 09, 2025 12:15 PM ET Company ParticipantsEric Benjamin - EVP & COOAna Maria Chadwick - EVP & CFOConference Call ParticipantsJeffrey Johnson - Senior Research AnalystJeffrey JohnsonI'm the Senior Medical Technology Analyst at Baird, and our next presentation this afternoon is from Insulet Corporation, a leader in the $4.7 billion global insulin pump market. With us today from Insulet, we're happy to have Chief Financial Officer Ana Maria Chadwick and Chief Op ...